The pioneering AbiProt® technology is a completely new concept in antibody discovery. It has proven capabilities to deliver antibodies against clinically meaningful targets, previously undruggable with conventional antibody technologies. AbiProt® is a scalable breakthrough innovation with potential to impact the lives of millions of patients.About AbiProt®
We focus on developing new antibody medicines in pain and aggressive-metastatic cancer. These conditions are in strong need of effective therapies that can only be solved by breakthrough science and innovation. The AbiProt technology has proven to deliver precision mAbs against clinically meaningful targets in these two disease areas.
We are a team of pharma professionals and young talent with strong scientific and business acumen. We have a proven track record of bringing drugs to the market, and we have a proven track record of excellence in science and product development. We are devoted to change the life of patients through innovation.About our Team
Recent newsMore news
14 October 2021 News
at the annual meeting of Society for Immunotherapy of Cancer, Nov 10 – 14, Washington DC, USA.
06 October 2021 News
in the INNOVATIVA FÖRETAG edition - October 2021
05 October 2021 News
for discoveries of receptors for temperature and touch.
Oblique Therapeutics has developed high affinity, stimuli-selective antibodies against the pain receptor TRPV1 in order to maximize pain relief and circumvent side effects. This asset is currently partnered with a top-20 pharma company.
Oblique has developed a pipeline of mutant selective aKRAS mAbs where the most advanced program targeting the KRAS G13D mutation has shown efficacy in a colorectal cancer xenograft model.